New standard of care for Limited-Stage Small-Cell Lung Cancer, summary by Estela Rodriguez 

Estela Rodriguez shared a post on X:

“Out today in ADRIATIC New England Journal of Medicine one of the most impactful American Society of Clinical Oncology – Lung presentations this year:

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer 

New standard of care

• N=760 Durvalumab x2 yrs post CRT
• mOS: 56 vs 33mos (HR 0.74)
• mPFS: 16.6 vs 9.2 mos (HR 0.76).”

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Authors: Ying Cheng, David R. Spigel, Byoung Chul Cho, Konstantin K. Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe,  Eva Lotte Buchmeier,  John Wen-Cheng Chang,  Yoshimasa Shiraishi,  Sema Sezgin Goksu,  Andrzej Badzio, Anhui Shi,  Davey B. Daniel, Nguyen Thi Thai Hoa, Milada Zemanova, Helen Mann, Hema Gowda, Haiyi Jiang and Suresh Senan.

Source: Estela Rodriguez/X

Dr. Estelamari (Estela) Rodriguez is an Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is a board certified in medical oncology and hematology. In the past, she was the Medical Director Thoracic Oncology at Mount Sinai Medical Center Miami Beach. Dr. Rodriguez has a special interest in the early detection of lung cancer and increasing access to clinical trials. She is a community leader and mentor to many women and minorities in medicine. Her passion is community engagement and empowering women to be advocates for their health and profession.